Comorbidities (with/without) | (1) GG | (2) TG | (3) TT | (1)vs.(2)vs.(3) F/x^{2}, P value | (1)vs.(2) F/x^{2}, P value |
(1)vs.(2) OR (95% CI) | (1)vs.(3) F/x^{2}, P value |
(1)vs.(3) OR (95%CI) | (2)vs.(3) F/x^{2}, P value |
(2)vs.(3) OR (95%CI) | |
---|---|---|---|---|---|---|---|---|---|---|---|
Hypertention | W/O^{a} | 198/110 | 340/226 | 175/120 | 1.952,0.377 | – | 1.19 | – | 1.08 | – | 0.91 |
(n = 713) | %^{b} | 64.3 | 60.1 | 59.3 | (0.91–1.44) | (0.79–1.48) | (0.69–1.20) | ||||
Diabetes | W/O | 48/270 | 109/471 | 54/241 | 2.033,0.362 | – | 0.95 | – | 1.23 | – | 1.29 |
(n = 211) | %^{b} | 15.1 | 18.8 | 18.3 | (0.60–1.51) | (0.70–2.15) | (0.79–2.12) | ||||
Hyperlipidaemia | W/O | 215/106 | 387/202 | 206/95 | 0.684,0.711 | – | 1.17 | – | 1.39 | – | 1.2 |
(n = 808) | %^{b} | 67.0 | 65.7 | 68.4 | (0.87–1.59) | (0.91–1.99) | (0.86–1.63) | ||||
Obesity | W/O | 234/63 | 411/140 | 209/73 | 2.276,0.320 | – | 1.44 | – | 1.75 | – | 1.21 |
(n = 854) | %^{b} | 78.8 | 74.6 | 74.1 | (1.09–1.90) | (1.26–2.43) | (0.90–1.64) | ||||
Tophi | W/O | 62/214 | 116/414 | 68/202 | 1.137,0.566 | – | 1.02 | – | 0.84 | – | 0.83 |
(n = 246) | %^{b} | 22.5 | 21.9 | 25.2 | (0.71–1.44) | (0.57–1.25) | (0.59–1.17) | ||||
Nephrolithiasis | W/O | 62/231 | 109/450 | 39/267 | 8.495,0.014 | 0.331,0.565 | 0.78 | 7.561,0.006 | 0.54 | 6.361,0.012 | 0.60 |
(n = 210) | %^{b} | 21.2 | 19.5 | 12.7 | (0.55–1.12) | (0.35–0.84) | (0.41–0.90) | ||||
CKD | W/O | 159/145 | 306/251 | 179/106 | 7.291,0.026 | 0.550,0.459 | 0.90 | 6.637,0.010 | 1.54 | 4.781,0.029 | 1.39 |
(n = 854) | %^{b} | 52.3 | 54.9 | 62.8 | (0.68–1.19) | (1.11–2.14) | (1.03–1.86) | ||||
CKD stage = 1 (n = 540) | 134 | 259 | 147 | 52.478,< 0.001 | |||||||
%^{c} | 44.1 | 46.5 | 51.6 | ||||||||
CKD stage≥2 (n = 104) | 25 | 47 | 32 | 7.288,0.026 | |||||||
%^{c} | 8.2 | 8.4 | 11.2 | ||||||||
CKD stage≥3 (n = 13) | 2 | 4 | 7 | 2.923,0.232 | |||||||
%^{c} | 0.6 | 0.7 | 2.5 |